Merck and Moderna Demonstrate High Manufacturing Success for Personalized mRNA Cancer Vaccine in Phase 3 Trial
Merck and Moderna have reported significant success in the manufacturing and delivery of their personalized mRNA cancer vaccine, intismeran autogene, during the Phase 3 INTerpath-001 trial for high-risk melanoma. The companies successfully provided the custom-made vaccine to 99% of patients in the treatment arm, demonstrating the feasibility of deploying this complex, individualized therapy on a large scale. This achievement is crucial because these vaccines are custom-made for each patient using samples from their unique tumors obtained during resection. The manufacturing process involves sequencing patient tumor tissue to identify specific mutational signatures, then writing a personalized synthetic mRNA code for up to 34 neoantigens. This code instructs the immune system on how to combat the unique cancer. The trial, which included 1,137 patients with resected stage 2b to 4 melanoma, also showed that the vaccine, when paired with Merck’s Keytruda, reduced the risk of recurrence or death by 42%. The stud...
